US Pharma MarketingEncoded closes $275M Series F for Dravet syndrome drug
The precision genetic medicine biotech also said it hopes to grow its manufacturing footprint and launch another program into the clinic next year. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The…
Encoded Therapeutics has tacked on $275 million in new capital, closing a Series F round led by GV and an undisclosed healthcare investor.
The precision genetic medicine biotech said Wednesday that ...
Source: Endpoints News